Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma
References (32)
- et al.
Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma
Ann Allergy Asthma Immunol
(2002) - et al.
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy
Chest
(2001) - et al.
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
J Allergy Clin Immunol
(2000) - et al.
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
J Allergy Clin Immunol
(1999) - et al.
Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma
J Allergy Clin Immunol
(2003) - et al.
Decrease in asthma mortality rate in Israel from 1991–1995: Is it related to increased use of inhaled corticosteroids?
J Allergy Clin Immunol
(2000) - et al.
Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma
Chest
(2002) - et al.
Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs
J Allergy Clin Immunol
(2002) - et al.
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies
J Allergy Clin Immunol
(2004) - et al.
Adherence to asthma controller medication regimens
Respir Med
(2005)
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
J Clin Epidemiol
Expert panel report 2: Guidelines for the diagnosis and management of asthma
Global strategy for asthma management and prevention
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma
Thorax
Adherence to HAART in clinical trials vs clinical care setting
Int Conf AIDS
Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients
J Clin Pharm Ther
Cited by (35)
Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England
2022, Respiratory MedicineCitation Excerpt :Increasing the ICS dose puts the patient at increased risk of side effects (and their associated cost) [30,31]; monoclonal antibodies, although effective and with minimal side effects [32], are expensive and are indicated only for specific subsets of patients; and adding an oral therapy increases treatment complexity, with theophylline use complicated by a narrow therapeutic index, in that the toxic dose is only slightly above the therapeutic dose [22]. In this context, the addition of a LAMA to therapy is a sensible choice – especially as part of a SITT, given simplification of maintenance therapy to a single inhaler can be expected to optimise adherence and persistence [25–28], and is also an easier treatment option for patients than using multiple inhalers. The current analyses provide additional support to the use of add-on LAMA therapy: not only was high-dose BDP/FF/G £2323 cheaper than high-dose BDP/FF plus tiotropium, but BDP/FF/G gained 0.017 additional QALYs, resulting in the SITT being dominant.
Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study
2017, Respiratory MedicineCitation Excerpt :LABA and ICS can be administered via separate inhalers or combined in one inhaler. Advantages of fixed-dose ICS/LABA inhalers include greater patient convenience, an increase in patient adherence as a result of simplification of the regime [10,11] and elimination of the possibility of LABA monotherapy and its attendant risks [12]. Treatment with a fixed combination of the ICS, fluticasone propionate, and the LABA, formoterol fumarate (fluticasone propionate/formoterol fumarate [FP/FORM]), as an aerosol suspension in a hydrofluoroalkane (HFA)-based pressurised metered-dose inhaler (pMDI) is associated with greater efficacy than treatment with each its components (fluticasone or formoterol) administered as monotherapy [13–16].
Pulmonary vascular changes in asthma and COPD
2014, Pulmonary Pharmacology and TherapeuticsAdherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD
2013, Respiratory MedicineCitation Excerpt :However, this is the only study demonstrating such data, and this area requires further research. Multiple-inhaler use has been associated with higher rates of non-adherence than single-inhaler use in both asthma and COPD patients – potentially because of the increased complexity introduced by the additional inhaler(s).32,58–60 Although one study found that certain inhaler types may be associated with higher rates of adherence than others in patients with asthma receiving ICS,61 data in this area are lacking and it is important to note that individual patients will have different device preferences.
Comparison of effectiveness between beclomethasone dipropionate and fluticasone propionate in treatment of children with moderate asthma
2010, World Allergy Organization JournalCitation Excerpt :This could be because of differences in pharmacokinetics and pharmacodynamics of FP and BDP 8. Although the results of our study was in agreement with some previous studies toward benefit of FP than BDP,9–11 the studies by Nong et al 12 and Karakoc et al 13 did not find any significant difference in lung function improvement and symptom scores in asthmatic children receiving either BDP or FP. However, these studied might be limited by the fact that they considered half dose of FP than BDP in their study 13.
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials
2019, The LancetCitation Excerpt :However, the addition of tiotropium requires patients to use two different inhalers of different design with different instructions for use, and often with different dosing regimens. Such a combination is not only inconvenient for patients and health-care providers who instruct on correct inhaler use, but can negatively affect treatment adherence and persistence.6–9 A single-inhaler triple therapy consisting of an extrafine formulation (ie, with mass median aerodynamic diameter <2 μm) of the inhaled corticosteroid beclometasone dipropionate, the long-acting β2 agonist formoterol fumarate, and the long-acting muscarinic antagonist glycopyrronium (known as BDP/FF/G from hereon) delivered via a pressurised metered-dose inhaler is in development for patients with asthma.
Preliminary results from this study were presented at the 2005 American Thoracic Society Annual Meeting, May 23, 2005, San Diego, California; and the 2006 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, March 18–22, 2006, San Antonio, Texas.